UPDATED Apr 18, 2024
Over $1bn in market cap, profitable and undervalued based on cash flows.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
AZN | UK£109.14 | -0.4% | -9.1% | UK£169.2b | UK£130.26 | PE35.3x | E16.4% | 2.1% | ||
GSK | UK£15.84 | -2.8% | 7.7% | UK£64.7b | UK£20.06 | PE13.1x | E9.4% | 3.7% |